AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 291 min read$BMY

Bristol Myers signals 2026 non-GAAP EPS $6.35-$6.55 while preparing for $1.5B-$2B Eliquis step-down in 2027 (NYSE:BMY)

Bristol-Myers Squibb (BMY) reported Q3 2026 with double-digit growth in its portfolio, according to CEO Christopher Boerner. The company raised its full-year guidance and expects 2026 non-GAAP EPS of $6.35-$6.55, while preparing for a $1.5B-$2B Eliquis revenue decline in 2027.

Original reporting
seekingalpha.com
Published Oct 29, 2026, 4:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 4:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BMY
Bullish
high confidence
Mentioned
$BMY
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$BMYBullishHigh
01

Why it matters

The guidance raise is a primary disclosure that can move the stock immediately.

02

Market read

New EPS guidance and cost‑saving plan provide fresh trading impetus for BMY.

03

What to watch

Potential regulatory or competitive pressures on Eliquis could offset cost‑saving benefits.

Relevance 8/10Novelty 8/10Timing: today

Background

Bristol Myers announced its Q3 2026 earnings call, highlighting double‑digit growth and an upgraded full‑year outlook.

Company-level read

Ticker impact

$BMYBullishHigh confidence
Context

Bristol Myers raised its 2026 non‑GAAP EPS guidance to $6.35‑$6.55 and announced a $1.5B‑$2B Eliquis step‑down in 2027, a fresh material forecast update.

Expected impact

upside pressure as investors price in higher EPS expectations

Evidence & confidence

The new EPS range exceeds prior expectations and includes a sizable cost reduction, which typically drives the stock higher in the short term.

Market effects

Sector

Higher guidance may lift peer biotech and pharma stocks as investors reassess sector earnings outlook.

Regional

U.S. market may see modest gains in healthcare index.

Global

Limited to U.S. and global pharma investors.

Counterpoint

What could challenge this read

If the guidance already priced in, the lift could be modest; focus on execution risk of the Eliquis step‑down.

Key entities

  • Executive
    Christopher Boerner

    CEO & Chairman of Bristol Myers who delivered the guidance update.

Read at source← All news

Related articles

OCT 29
$BMYMedAI 8/10

Bristol-Myers Squibb (BMY) Q3 2026 Earnings Call Transcript

Bristol-Myers Squibb (BMY) reported Q3 2026 earnings with 12% growth in its portfolio, driven by key brands like Reblozyl and Camzyos. The company raised full-year guidance and highlighted regulatory approvals, including Symvexis for multiple myeloma. Pipeline advancements and manufacturing investments were also discussed, with several key readouts expected by year-end and into 2027.

finance.yahoo.com2 min
OCT 29
$LLYMed

Drugmakers Shrug Off Trump Pricing Pressure With Record Revenue

Three major US drugmakers—Eli Lilly, Merck, and Bristol Myers Squibb—reported record quarterly revenue and raised annual forecasts, citing strong demand for treatments. Despite Trump's pricing pressure, shares rose significantly. The companies expect volume growth to offset any price reductions. The White House highlighted savings programs as accomplishments.

finance.yahoo.com2 min
OCT 29
$NVSLow

4 Long-Term Survival Results From ESMO 2026 Patients Should Know

Novartis reported 6-year data from the NATALEE trial showing Kisqali (ribociclib) reduced death risk by 19% in early breast cancer. Merck's Keytruda (pembrolizumab) showed 7-year survival benefits in kidney cancer. Bristol-Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated lasting survival in colorectal cancer. Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii) combinations showed 3-year survival gains in stomach/esophageal cancer. All treatments were FDA-approved previously.

curetoday.com3 min
OCT 29
$BMYMedAI 8/10

BMS Flounders As Opdivo Lags, Earnings Guidance Cut

Bristol Myers Squibb (BMY) reported Q3 adjusted earnings of $1.35 per share, beating estimates of $1.10, with revenue of $13.07B, also exceeding expectations. The company cut its full-year earnings guidance due to weaker-than-expected sales of its cancer drug, Opdivo. BMY shares declined on the news.

investors.com2 min